知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.048 秒)

    Design of CXC chemokine analogs for the treatment of human diseases
    1.
    发明申请
    Design of CXC chemokine analogs for the treatment of human diseases 审中-公开
    设计用于治疗人类疾病的CXC趋化因子类似物

    公开(公告)号：US20070160574A1

    公开(公告)日：2007-07-12

    申请号：US11649928

    申请日：2007-01-04

    申请人： Ahmed Merzouk ,  Hassan Salari

    发明人： Ahmed Merzouk ,  Hassan Salari

    IPC分类号： A61K38/19 ,  A61K39/395 ,  C07K14/52 ,  C07K16/24

    CPC分类号： C07K14/522 ,  A61K38/00

    摘要： The present invention generally relates to the design, preparation, derivation, and use of mimetics of CXC chemokines (CXCL1-CXCL17) in the prevention, treatment, and ameliorization of a wide variety of diseases and disorders. Generally speaking, this invention is directed to the design, synthesis, and use of chemokine analogs which bind to CXC chemokine receptors CXCR1-CXCR7, such that the analogs can be designed to affect the activity of the receptor, either as an agonist or an antagonist. The analogs can be useful for treating a wide variety of diseases and disorders, and can also serve as an adjunct to the treatment of a variety of diseases and disorders.

    摘要翻译： 本发明一般涉及CXC趋化因子（CXCL1-CXCL17）的模拟物在多种疾病和病症的预防，治疗和改善中的设计，制备，衍生和应用。 一般来说，本发明涉及结合CXC趋化因子受体CXCR1-CXCR7的趋化因子类似物的设计，合成和使用，使得类似物可被设计成影响受体的活性，作为激动剂或拮抗剂 。 类似物可用于治疗各种疾病和病症，并且还可用作治疗各种疾病和病症的辅助物质。

    Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
    2.
    发明申请
    Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases 审中-公开
    干扰素诱导蛋白-10（IP-10或CXCL10）趋化因子类似物用于治疗人类疾病

    公开(公告)号：US20070116669A1

    公开(公告)日：2007-05-24

    申请号：US11590210

    申请日：2006-10-30

    申请人： Ahmed Merzouk ,  Donald Wong ,  Hassan Salari

    发明人： Ahmed Merzouk ,  Donald Wong ,  Hassan Salari

    IPC分类号： A61K38/19 ,  C07K14/52 ,  C07K16/24 ,  A61K39/395

    CPC分类号： C07K14/522 ,  A61K38/00

    摘要： This invention is directed to peptide analogs of interferon-inducible protein-10 (IP-10 or CXCL10) chemokine that bind to the CXCR3 receptor or any other receptor in which IP-10 analogs can bind to as a ligand, such that the analogs can be designed to serve as agonists or antagonists of IP-10 chemokine. The analogs can be used to prevent, treat, or ameliorate the symptoms of, a disease.

    摘要翻译： 本发明涉及与CXCR3受体结合的干扰素诱导蛋白-10（IP-10或CXCL10）趋化因子的肽类似物或其中IP-10类似物可以结合作为配体的任何其它受体，使得类似物可以 被设计用作IP-10趋化因子的激动剂或拮抗剂。 类似物可用于预防，治疗或改善疾病的症状。

    Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
    3.
    发明授权
    Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis 失效
    用于调节新血管生长的循环肽及其在治疗性血管生成中的用途

    公开(公告)号：US07368425B2

    公开(公告)日：2008-05-06

    申请号：US11388542

    申请日：2006-03-24

    申请人： Ahmed Merzouk ,  Carolina Abramovich ,  Hassan Salari

    发明人： Ahmed Merzouk ,  Carolina Abramovich ,  Hassan Salari

    IPC分类号： A61K38/16 ,  C07K14/00

    CPC分类号： A61K38/12

    摘要： The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The teachings are generally directed to compositions comprising SDF-1 mimetics, as well as methods that include the use of SDF-1 mimetics to induce neo-vessel formation. The disclosure also teaches articles of manufacture that can be useful in practicing the methods taught herein.

    摘要翻译： 本公开内容教导人趋化因子的类似物及其在预防，治疗和改善可受益于治疗性血管生成的疾病中的方法。 该教导通常涉及包含SDF-1模拟物的组合物，以及包括使用SDF-1模拟物诱导新血管形成的方法。 本公开还教导可用于实践本文教导的方法的制造品。

    Chemokine analogs for the treatment of human diseases
    4.
    发明申请
    Chemokine analogs for the treatment of human diseases 审中-公开
    趋化因子类似物用于治疗人类疾病

    公开(公告)号：US20070066523A1

    公开(公告)日：2007-03-22

    申请号：US11494232

    申请日：2006-07-26

    申请人： Ahmed Merzouk ,  Donald Wong ,  Hassan Salari

    发明人： Ahmed Merzouk ,  Donald Wong ,  Hassan Salari

    IPC分类号： A61K38/16 ,  C07K14/475

    CPC分类号： C07K14/4718 ,  A61K38/00 ,  C07K14/523 ,  C07K14/5421

    摘要： The present invention is concerned with chemokine analogs, including IL-8 analogs, IP-10 analogs, MIP-1α analogs, RANTES analogs, I-309 analogs, MCP-1 analogs, and CCL28 analogs, that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and disorders. A therapeutically effective amount of the chemokine analog may be administered to a patient in need of such treatment.

    摘要翻译： 本发明涉及趋化因子类似物，包括IL-8类似物，IP-10类似物，MIP-1α类似物，RANTES类似物，I-309类似物，MCP-1类似物和CCL28类似物，其可用于治疗 各种疾病和病症，以及作为治疗各种疾病和病症的辅助物质。 趋化因子类似物的治疗有效量可以施用于需要这种治疗的患者。

    Novel chemokine mimetics synthesis and their use
    5.
    发明申请
    Novel chemokine mimetics synthesis and their use 失效
    新型趋化因子模拟物合成及其应用

    公开(公告)号：US20060252687A1

    公开(公告)日：2006-11-09

    申请号：US11393769

    申请日：2006-03-29

    申请人： Ahmed Merzouk ,  Abdelkrim Habi ,  Donald Wong ,  Hassan Salari

    发明人： Ahmed Merzouk ,  Abdelkrim Habi ,  Donald Wong ,  Hassan Salari

    IPC分类号： A61K38/16

    CPC分类号： A61K38/12 ,  C07K14/521

    摘要： The present disclosure generally teaches compositions comprising SDF-1 mimetics and methods of using them to modulate an activity of a cell having an SDF-1 receptor by binding the SDF-1 receptor to an SDF-1 mimetic. The cell can be a hematopoietic cell, for example, and can be selected from a group consisting of hematopoietic stem cells, hematopoietic progenitor cells, primitive granulocytes, primitive erythroid cells, leukocytes, and neutrophils. In some embodiments, the activity can include the rate of multiplication of the cell or, where the cell is a quiescent cell, the binding can repress the activation of the quiescent cell. Other embodiments of the present invention are taught herein.

    摘要翻译： 本公开通常教导包含SDF-1模拟物的组合物和使用它们通过将SDF-1受体结合到SDF-1模拟物来调节具有SDF-1受体的细胞的活性的方法。 细胞可以是例如造血细胞，并且可以选自造血干细胞，造血祖细胞，原始粒细胞，原始红细胞，白细胞和嗜中性粒细胞。 在一些实施方案中，活性可以包括细胞的增殖速率，或者当细胞是静止细胞时，结合可以抑制静止细胞的活化。 本文教导了本发明的其它实施例。

    Therapeutics for chemokine mediated diseases
    7.
    发明授权
    Therapeutics for chemokine mediated diseases 失效
    趋化因子介导的疾病的治疗剂

    公开(公告)号：US06706767B2

    公开(公告)日：2004-03-16

    申请号：US09767378

    申请日：2001-01-22

    申请人： Geeta Saxena ,  Christopher R. Tudan ,  Hassan Salari

    发明人： Geeta Saxena ,  Christopher R. Tudan ,  Hassan Salari

    IPC分类号： A61K31122

    CPC分类号： A61K31/473 ,  A61K31/00 ,  A61K31/015 ,  A61K31/11 ,  A61K31/122 ,  Y02A50/411

    摘要： The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds including uses in the treatment of disease states mediated by chemokines. The relevant chemokines may for example be monocyte chemoattractant protein-one (MCP-1) or interleukin-8 (IL-8), and the relevant chemokine receptors may for example be corresponding chemokine receptors (CCR-2, CCR-4, CXCR-1, and CXCR-2). In one aspect, the invention provides for the use of phenanthrene-9,10-dione in the treatment of multiple sclerosis.

    摘要翻译： 本发明提供趋化因子受体结合化合物的治疗和生物学应用，包括用于治疗由趋化因子介导的疾病状态的用途。 相关的趋化因子可以是例如单核细胞趋化蛋白一（MCP-1）或白细胞介素-8（IL-8），并且相关趋化因子受体可以例如是相应的趋化因子受体（CCR-2，CCR-4，CXCR- 1和CXCR-2）。 一方面，本发明提供了用于治疗多发性硬化症的菲-9,10-二酮的用途。

    Bicyclic aromatic chemokine receptor ligands
    8.
    发明授权
    Bicyclic aromatic chemokine receptor ligands 失效
    双环芳香趋化因子受体配体

    公开(公告)号：US06693134B2

    公开(公告)日：2004-02-17

    申请号：US09993352

    申请日：2001-11-13

    申请人： Geeta Saxena ,  Christopher R. Tudan ,  Ahmed Merzouk ,  Hassan Salari

    发明人： Geeta Saxena ,  Christopher R. Tudan ,  Ahmed Merzouk ,  Hassan Salari

    IPC分类号： A61K3138

    CPC分类号： A61K31/167 ,  A61K31/00 ,  A61K31/11 ,  A61K31/166 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/422 ,  A61K31/535

    摘要： The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as naphthoic acid derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokine may for example be stromal cell-derived factor (SDF)-1, and the relevant chemokine receptors may for example be corresponding chemokine receptor (CXCR-4). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of 3-Hydroxy-2-naphthoic acid in the treatment of disease.

    摘要翻译： 本发明提供趋化因子受体结合化合物（包括趋化因子受体配体如趋化因子受体激动剂或拮抗剂）如萘甲酸衍生物的治疗和生物学应用，包括用于治疗由趋化因子介导的疾病状态的用途。 相关的趋化因子可以例如是基质细胞衍生因子（SDF）-1，并且相关的趋化因子受体可以例如是相应的趋化因子受体（CXCR-4）。 在其它方面，本发明提供相应的药用组合物和治疗方法。 一方面，例如，本发明提供3-羟基-2-萘甲酸在治疗疾病中的用途。

    Phosphonates as anti-inflammation agents
    9.
    发明授权
    Phosphonates as anti-inflammation agents 失效
    膦酸盐作为抗炎剂

    公开(公告)号：US5219845A

    公开(公告)日：1993-06-15

    申请号：US835732

    申请日：1992-02-11

    申请人： Hassan Salari ,  Robert Bittman

    发明人： Hassan Salari ,  Robert Bittman

    IPC分类号： C07F9/30 ,  C07F9/40

    CPC分类号： C07F9/4081 ,  C07F9/301 ,  C07F9/303 ,  C07F9/4006 ,  C07F9/4075

    摘要： The invention pertains to the synthesis and use as therapeutic agents of a group of substances with a glycerol backbone or aliphatic chain structure linked to a phosphorus atom and a polar head group. Depending on the polar head group, the substance has anti-cancer, anti-inflammatory, anti-allergy or anti-cardiovascular disease properties. Compounds of the formula: ##STR1## wherein n is 0 to 14 and R.sub.1 is an alkyl group of C.sub.12 -C.sub.20, R.sub.2 is a methyl group, and wherein R.sub.3 is an inositol analog head group, a (CH.sub.2).sub.m N.sup.+ (CH.sub.3).sub.3 group with m=2 to 10, a serine head group, or an ethanolamine head group, or of the formula ##STR2## wherein R.sub.1 and R.sub.2 are as described above, n=0 or 1, and R.sub.3 is (CH.sub.2).sub.m N.sup.+ (CH.sub.3).sub.3 (m=2-10) are claimed. This invention also pertains to the synthesis and use as therapeutic agents of a group of substances that have no glycerol backbone but have an aliphatic chain structure linked directly to a phosphorus atom of the general formula R--P(O)(O.sup.-)OR' wherein R is a long-chain alkyl group such as hexadecyl or octadecyl and R' is a head group such as choline, glycerol, inositol, ethanolamine, or serine.

    摘要翻译： 本发明涉及作为具有与磷原子和极性头基连接的甘油骨架或脂肪链结构的物质组的治疗剂的合成和用途。 根据极性头组，该物质具有抗癌，抗炎，抗过敏或抗心血管疾病的特性。 下式的化合物：其中n为0至14，R 1为C 12 -C 20的烷基，R 2为甲基，其中R 3为肌醇类似物头基，（CH 2）m N +（CH 3）3 m = 2至10的丝氨酸基团或乙醇胺头基团，或式IMAMA的化合物，其中R 1和R 2如上所述，n = 0或1，且R 3为（CH 2）m N +（CH 3） ）3（m = 2-10）。 本发明还涉及作为不具有甘油骨架但具有与通式RP（O）（O）OR'的磷原子直接连接的脂肪链结构）的一组物质的治疗剂的合成和用途，其中R 是长链烷基如十六烷基或十八烷基，R'是头基，例如胆碱，甘油，肌醇，乙醇胺或丝氨酸。